Table of contents

Clinical/translational cancer immunotherapy

• Original research: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis (30 August, 2021)

  Yvette Robbins, Jay Friedman, Paul E Clavijo, Cem Sievers, Ke Bai, Renee N Donahue, Jeffrey Schlom, Andrew Sinkoe, Houssein Abdul Sater, James L Gulley, Scott Norberg, Christian S Hinrichs, Clint Allen
• Original research: IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) (27 August, 2021)

  Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz, Lauren Harshman, Leonard Appleman, Paul Monk, Rhonda L Bitting, Omer Kucuk, Frederick Millard, John D Seigne, Steven P Fling, Holden T Maecker, Caroline Duault, Nirasha Ramchurren, Bruce Hess, Leonard D’Amico, Andreanne Lacroix, Judith C Kaiser, Michel Morre, Anne Grégoire, Martin Cheever, Evan Y Yu, Lawrence Fong
• Original research: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival (27 August, 2021)

  Mario Mandalá, James Larkin, Paolo A Ascierto, Michele Del Vecchio, Helen Gogas, C Lance Cowey, Ana Arance, Stéphane Dalle, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Jose Lutzky, Luis De La Cruz-Merino, Victoria Atkinson, Petr Arenberger, Andrew Hill, Leslie Fecher, Michael Millward, Nikhil I Khushalani, Veerle de Pril, Maurice Lobo, Jeffrey Weber
• Original research: Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response (27 August, 2021)

  Lele Zhang, Jiacheng Huang, Xiaona Chen, Caixu Pan, Yong He, Rong Su, Danjing Guo, Shengyong Yin, Shuai Wang, Lin Zhou, Jianxiang Chen, Shusen Zheng, Yiting Qiao
• Original research: Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial (26 August, 2021)

  Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Ernest Nadal, Yago Garitaonaindía, Amelia Insa, Joaquín Mosquera, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodriguez-Abreu, Alex Martinez-Marti, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massuti, Raquel Laza-Briviesca, Marta Casarrubios, Aránzazu García-Grande, Atocha Romero, Fernando Franco, Mariano Provencio
• Original research: Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal (25 August, 2021)

  Sho Isoyama, Shigeyuki Mori, Daisuke Sugiyama, Yasuhiro Kojima, Yasuko Tada, Kohei Shitara, Kunihiko Hinohara, Shingo Dan, Hiroyoshi Nishikawa
• Original research: Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer (25 August, 2021)

  Chrisann Kyi, Ekaterina Doubrovina, Qin Zhou, Sara Kravetz, Alexia Iasonos, Carol Aghajanian, Paul Sabbatini, David Spriggs, Richard J O'Reilly, Roisin E O’Cearbhaill
• Original research: Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors (24 August, 2021)

  Filippo Pietrantonio, Sara Lonardi, Francesca Corti, Gabriele Infante, Maria Elena Elez, Marwan Fakih, Priya Jayachandran, Aakash Tushar Shah, Massimiliano Salati, Elisabetta Fenocchio, Lisa Salvatore, Giuseppe Curigliano, Chiara Cremolini, Margherita Ambrosini, Javier Ros, Rossana Intini, Floriana Nappo, Silvia Damian, Federica Morano, Giovanni Fucà, Michael Overman, Rosalba Miceli
• Original research: Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) (24 August, 2021)

  Natasha B Leighl, Mary W Redman, Naiyer Rizvi, Fred R Hirsch, Philip C Mack, Lawrence H Schwartz, James L Wade, William J Irvin, Sreekanth C Reddy, Jeffrey Crawford, Jeffrey D Bradley, Thomas E Stinchcombe, Suresh S Ramalingam, Jieling Miao, Katherine Minichiello, Roy S Herbst, Vassiliki A Papadimitrakopoulou, Karen Kelly, David R Gandara
• Original research: Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma (19 August, 2021)

  Sapna P Patel, Gina R Petroni, Jason Roszik, Walter C Olson, Nolan A Wages, Kimberly A Chianese-Bullock, Mark Smolkin, Nikole Varhegyi, Elizabeth Gaughan, Kelly T Smith, Kathleen Haden, Emily H Hall, Sacha Gnjatic, Patrick Hwu, Craig L Slingluff
• Original research: Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis (19 August, 2021)

  Danny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, Alexander Guminski, Anne Lynn S Chang, Karl D Lewis, Annette M Lim, Leonel Hernandez-Aya, Brett G M Hughes, Dirk Schadendorf, Axel Hauschild, Alesha A Thai, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Siyu Li, Zhen Chen, Emmanuel Okoye, Chieh-I Chen, Vera Mastey, Medha Sasane, Israel Lowy, Matthew G Fury, Michael R Migden
• Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro (19 August, 2021)

  Aneta Ledererova, Lenka Dostalova, Veronika Kozlova, Helena Peschelova, Adriana Ladungova, Martin Culen, Tomas Loja, Jan Verner, Sarka Pospisilova, Michal Smida, Veronika Mancikova
• Original research: First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas (13 August, 2021)

  Sarina A Piha-Paul, Ravit Geva, Tira J Tan, Darren WT Lim, Cinta Hierro, Toshikiko Doi, Osama Rahma, Alexander Lesokhin, Jason John Luke, Javier Otero, Lisa Nardi, Angad Singh, Alexandros Xyrafas, Xinhui Chen, Jennifer Mataraza, Philippe L Bedard
• Original research: Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers (11 August, 2021)

  Jarushka Naidoo, Karisa C Schreck, Wei Fu, Chen Hu, Alexander Carvajal-Gonzalez, Roisin M Connolly, Cesar A Santa-Maria, Evan J Lipson, Matthias Holdhoff, Patrick M Forde, Christopher Douville, Joanne Riemer, Amanda Barnes, Kristin J Redmond, Lawrence Kleinberg, Brandi Page, Nafi Aygun, Kenneth W Kinzler, Nickolas Papadopoulos, Chetan Bettegowda, Arun Venkatesan, Julie R Brahmer, Stuart A Grossman
• Original research: Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) (11 August, 2021)

  Michael J Wagner, Megan Othus, Sandip P Patel, Chris Ryan, Ashish Sangal, Benjamin Powers, G Thomas Budd, Adrienne I Victor, Chung-Tsen Hsueh, Rashmi Chugh, Suresh Nair, Kirsten M Leu, Mark Agulnik, Elad Sharon, Edward Mayerson, Melissa Plets, Charles Blanke, Howard Streicher, Young Kwang Chae, Razelle Kurzrock
• Original research: Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T (10 August, 2021)

  Tanya Dorff, Yosuke Hirasawa, Jared Acoba, Ian Pagano, David Tamura, Sumanta Pal, Minlu Zhang, Rebecca Waitz, Abhilash Dhal, Winston Haynes, John Shon, Mark Scholz, Hideki Furuya, Owen T M Chan, Jeffrey Huang, Charles Rosser
• Original research: HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial (2 August, 2021)

  Noor Alida Maria Bakker, Jossie Rotman, Marc van Beurden, Henry J MAA Zijlmans, Maartje van Ruiten, Sanne Samuels, Bastiaan Nuijen, Jos Beijnen, Karin De Visser, John Haanen, Ton Schumacher, Tanja D de Gruijl, Ekaterina S Jordanova, Gemma G Kenter, Joost H van den Berg, Nienke E van Trommel
• Original research: Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia (2 August, 2021)

  Jeong Uk Choi, Na Kyeong Lee, Hyungseok Seo, Seung Woo Chung, Taslim A Al-Hilal, Seong Jin Park, Seho Kweon, Nuri Min, Sang Kyoon Kim, Seohyun Ahn, Uk-Il Kim, Jin Woo Park, Chang-Yuil Kang, In-San Kim, Sang Yoon Kim, Kyungjin Kim, Youngro Byun